By Healthcare investor, Archimed, has acquired and simultaneously merged US-based Symbio, and Germany-based Proinnovera in an all-equity deal. Symbio and Proinnovera are CROs. The merged group, Symbio Proinnovera, provides consulting, testing and clinical research through every development stage, from conception to global regulatory approval and commercialization. “We’ve rejected partnership offers in the past from private equity…
